$SRNE WTF?!? $MRNA finance.yahoo.com/news/mode... As the coronavirus tightens its grip on the world, the stakes for Moderna — and a potential COVID-19 treatment — are high. Typically, the vaccine industry is not as profitable as therapies, and a treatment that falls short could be a devastating blow to a relatively young company. The mRNA vaccine technology the company is using has not yet been tested on the market, and production is more complex than traditional vaccines. The U.S. Food and Drug Administration has set a bar of 50% efficacy We have to make a profit’ If successful, a vaccine will actually be the 10-year-old company’s first product on the market. Despite significant taxpayer funding, as well as investors boosting its market capitalization to $29 billion, the biotech upstart will need to make a profit — and will consider that in its pricing, Bancel said.